David T. Crawford - Concepedia

Author

David T. Crawford

Also Known As

D T Crawford, D Todd Crawford, D. Todd Crawford, D.T Crawford, D.T. Crawford, D.Todd Crawford, DAVID T. CRAWFORD, David T. Crawford

Publications

Citations

H-Index

Concepts

All Affiliations

Pfizer (United States)University of Utah Sinai Hospital Johns Hopkins University

About

David T. Crawford is an author at Pfizer (United States) specializing in medicine, osteoporosis, and endocrinology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	17	2.4K
2	Health Sciences	5	5	850
3	Natural Sciences	2	2	481
4	Biochemistry	2	2	481
5	Engineering	1	1	40

David T. Crawford

Publications

2.9K

Citations

H-Index

Page 1

	Year	Citations
Leptin is a potent stimulator of bone growth in ob/ob mice Claire M. Steppan, David T. Crawford, Kristen L. Chidsey-Frink, Regulatory Peptides SclerostinBone Morphogenic ProteinHuman GrowthMedicinePhysiology	2000	515
THE HISTOCHEMICAL DEMONSTRATION OF LEUCINE AMINOPEPTIDASE Marvin M. Nachlas, David T. Crawford, Arnold M. Seligman Journal of Histochemistry & Cytochemistry Protein ChemistryCoupling AgentCellular EnzymologyBiochemistryHistochemical Localization	1957	421
Targeted Disruption of the Osteoblast/Osteocyte Factor 45 Gene (OF45) Results in Increased Bone Formation and Bone Mass Lori C. Gowen, Donna N. Petersen, Amy L. Mansolf, Journal of Biological Chemistry	2003	296
Deletion of the P2X<sub>7</sub>Nucleotide Receptor Reveals Its Regulatory Roles in Bone Formation and Resorption Hua Zhu Ke, Hong Qi, A. Frederik Weidema, Molecular Endocrinology SclerostinMolecular BiologyBone FormationRegulatory RolesOrthopaedic Surgery	2003	289
Effects of CP-336,156, a New, Nonsteroidal Estrogen Agonist/Antagonist, on Bone, Serum Cholesterol, Uterus, and Body Composition in Rat Models Hua Zhu Ke, Vishwas Paralkar, W A Grasser, Endocrinology GynecologyRat ModelsFemale Reproductive FunctionNonsteroidal Estrogen Agonist/antagonistOsteoporosis	1998	157
Proline-rich tyrosine kinase 2 regulates osteoprogenitor cells and bone formation, and offers an anabolic treatment approach for osteoporosis Leonard Buckbinder, David T. Crawford, Hong Qi, Proceedings of the National Academy of Sciences SclerostinCoupled ActionsHigh Bone MassBone FormationOsteoporosis	2007	154
Discovery and Preclinical Pharmacology of a Novel, Potent, Nonsteroidal Estrogen Receptor Agonist/Antagonist, CP-336156, a Diaryltetrahydronaphthalene Robert L. Rosati, Paul Da Silva Jardine, Kimberly O. Cameron, Journal of Medicinal Chemistry Molecular PharmacologyMedicineHormonal ReceptorAltmetric Attention ScoreGynecology	1998	131
Comparative effects of droloxifene, tamoxifen, and estrogen on bone, serum cholesterol, and uterine histology in the ovariectomized rat model Hua Zhu Ke, H.K. Chen, Hollis A. Simmons, Bone Hormonal ContraceptiveSerum CholesterolMedicineOvariectomized Rat ModelGynecology	1997	122
A Novel, Non-Prostanoid EP2 Receptor-Selective Prostaglandin E2 Agonist Stimulates Local Bone Formation and Enhances Fracture Healing Mei Li, Hua Zhu Ke, Hong Qi, Journal of Bone and Mineral Research	2003	116
Droloxifene, a new estrogen antagonist/agonist, prevents bone loss in ovariectomized rats. H.Z. Ke, Hollis A. Simmons, C.M. Pirie, Endocrinology GynecologyPharmacotherapyOsteoporosisOrthopaedic SurgeryOvarian Cancer	1995	114

Page 1